The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Far too many kids and families live in dread over the weekly nausea and vomiting caused by
methotrexate - a medicine that controls joint swelling in Juvenile Arthritis patients. If
methotrexate is not tolerated, expensive alternative biological medications may be started.
This registry-based pragmatic randomized controlled trial will evaluate if routine
premedication with the anti-emetic drug Ondansetron, reduces nausea and vomiting and
increases the proportion of children able to continue methotrexate. By preventing nausea
before it starts, the investigators hope to give kids and families a better quality of life
and see a more cost-effective use of medication.